Use

This panel evaluates thrombotic risk through measurement of key biomarkers indicative of fibrinolysis and thrombin generation, such as D‑Dimer, Fibrin Monomer, Prothrombin Fragment 1.2, and Thrombin‑Antithrombin (TAT). These markers collectively assist in assessing hypercoagulable states and guiding clinical decision‑making in suspected thrombosis.

Not provided.